Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Sun, Daqing, Li, Zhihong, Rew, Yosup, Gribble, Michael, Bartberger, Michael D., Beck, Hilary P., Canon, Jude, Chen, Ada +42 more·2014·Journal of Medicinal Chemistry

DOI 10.1021/jm401753e

Cited by (306)

Items 101–200 of 306

Single-atom-nickel photocatalytic site-selective sulfonation of enamides to access amidosulfones
Jianjing Yang, Zongzhao Sun, Kelu Yan, Haozhe Dong, Hongyan Dong, Jiakai Cui, Xutao Gong, Shilin Han, Limin Huang, Jiangwei Wen · 2021 · Green Chemistry
FBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex
Benita Sjögren, Steven M. Swaney, Richard R. Neubig · 2015 · PLoS ONE
Molecular Probing of the HPV-16 E6 Protein Alpha Helix Binding Groove with Small Molecule Inhibitors
Anne Rietz, Dino P. Petrov, Matthew D. Bartolowits, Marsha L. DeSmet, Vincent Jo Davisson, Elliot J. Androphy · 2016 · PLoS ONE
Spirooxadiazoline oxindoles with promising in vitro antitumor activities
Carlos J. A. Ribeiro, Joana D. Amaral, Cecília M. P. Rodrigues, Rui Moreira, Maria M. M. Santos · 2015 · MedChemComm
Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition
Prashanth Jyothi Prabakaran, Amal M. Javaid, Adam D. Swick, Lauryn R. Werner, Kwangok P. Nickel, Emmanuel Sampene, Rong Hu, Irene M. Ong, Justine Y. Bruce, Gregory K. Hartig et al. · 2017 · Clinical Cancer Research
Roles of computational modelling in understanding p53 structure, biology, and its therapeutic targeting
Yaw Sing Tan, Yasmina Mhoumadi, Chandra S. Verma · 2019 · Journal of Molecular Cell Biology
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Hongyi Zhao, Minhang Xin, San‐Qi Zhang · 2023 · Drug Development Research
MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation
Pellot Ortiz, Karolina I., Rechberger, Julian S., Nonnenbroich, Leo F., Daniels, David J., Sarkaria, Jann N. · 2023 · Biomedicines
Structural States of Hdm2 and HdmX: X‐ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes
Joerg A. Kallen, Aude Izaac, Suzanne Chau, Emmanuelle Wirth, Joseph G. Schoepfer, Robert Mah, Achim Schlapbach, Stefan Stutz, Andrea Vaupel, Vito Guagnano et al. · 2019 · ChemMedChem
Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Maryam Zanjirband, Soheila Rahgozar · 2019 · Current Drug Targets
Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells
Liren Jiang, Natasha Malik, Pilar Acedo, Joanna Zawacka‐Pankau · 2019 · Cell Death Discovery
Iron(III)-Mediated Oxysulfonylation of Enamides with Sodium and Lithium Sulfinates
Philipp Kramer, Miro Halaczkiewicz, Yu Sun, Harald Kelm, Georg Manolikakes · 2020 · The Journal of Organic Chemistry
A Regio‐ and Stereodivergent Synthesis of Homoallylic Amines by a One‐Pot Cooperative‐Catalysis‐Based Allylic Alkylation/Hofmann Rearrangement Strategy
Colin M. Pearson, James W. B. Fyfe, Thomas N. Snaddon · 2019 · Angewandte Chemie
Explore drug-like space with deep generative models
Jianmin Wang, Jiashun Mao, Meng Wang, Xiangyang Le, Yunyun Wang · 2023 · Methods
Recent Synthetic Approaches towards Small Molecule Reactivators of p53
Jerson Lima Silva, Carolina G. S. Lima, Luciana Pereira Rangel, Giulia D. S. Ferretti, Fernanda P. Pauli, Ruan C. B. Ribeiro, Thais B. Silva, Fernando de Carvalho da Silva, Vı́tor F. Ferreira · 2020 · Biomolecules
Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma
Ruth Eichner, Vanesa Fernández‐Sáiz, Bianca‐Sabrina Targosz, Florian C. Bassermann · 2018 · International review of cytology
Therapeutic Strategies to Activate p53
Angelo Aguilar, Shaomeng Wang · 2022 · Pharmaceuticals
Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2–p53 Interaction
Ming Yu, Yingcai Wang, Jiang Zhu, Michael D. Bartberger, Jude R. Canon, Ada Chen, David T. Chow, John E. Eksterowicz, Brian M. Fox, Jiasheng Fu et al. · 2014 · ACS Medicinal Chemistry Letters
Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran–oxindole derivatives as potent p53-MDM2 inhibitors
Changjin Ji, Shengzheng Wang, Shuqiang Chen, Shipeng He, Yan Jiang, Zhenyuan Miao, Jian Li, Chunquan Sheng · 2017 · Bioorganic & Medicinal Chemistry
Microsecond simulations of mdm2 and its complex with p53 yield insight into force field accuracy and conformational dynamics
George Anthony Pantelopulos, Sudipto Mukherjee, Vincent A. Voelz · 2015 · Proteins Structure Function and Bioinformatics
Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases
Nicole Blaquière, Elisia Villemure, Steven T. Staben · 2020 · Journal of Medicinal Chemistry
Discovery of novel polycyclic spiro-fused carbocyclicoxindole-based anticancer agents
Lidan Zhang, Wen Ting Ren, Xiaoyan Wang, Jiaying Zhang, Jie Liu, Lifeng Zhao, Xia Zhang · 2016 · European Journal of Medicinal Chemistry
p53 biology and reactivation for improved therapy in MDS and AML
Joanna Zawacka‐Pankau · 2024 · Biomarker Research
The Targeted Therapies for Osteosarcoma via Six Major Pathways
Shuxing Wang, Quanlei Ren, Guoqing Li, Xiaoxuan Zhao, Xing Zhao, Zhen Zhang · 2023 · Current Molecular Pharmacology
Reductive Transformations of Carbonyl Compounds Catalyzed by Rhodium Supported on a Carbon Matrix by using Carbon Monoxide as a Deoxygenative Agent
Niyaz Z. Yagafarov, Dmitry L. Usanov, Alexey P. Moskovets, N. D. Kagramanov, Victor I. Maleev, Denis Alexandrovich Chusov · 2015 · ChemCatChem
p53: An Attractive Therapeutic Target for Cancer
Krupa R. Patel, Hitesh D. Patel · 2019 · Current Medicinal Chemistry
Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action
Surendra Reddy Punganuru, Viswanath Arutla, Wei Zhao, Mehrdad Rajaei, Hemantkumar S. Deokar, Ruiwen Zhang, John K. Buolamwini, Kalkunte S. Srivenugopal, Wei Wang · 2020 · Cells
p53: from understanding its structure to advances in therapeutic targeting
Wenhua Wang, Xia Liu, Hengqi Liu, Hassan Abolhassani, Han Yan, Huilai Zhang, Xianhuo Wang · 2026 · Signal Transduction and Targeted Therapy
The p53 pathway in vasculature revisited: A therapeutic target for pathological vascular remodeling?
Xiaopei Cui, Guopin Pan, Ye Chen, Xiaosun Guo, Tengfei Liu, Jing Zhang, Xiaofan Yang, Mei Cheng, Haiqing Gao, Fan Jiang · 2021 · Pharmacological Research
Development of a Commercial Process To Prepare AMG 232 Using a Green Ozonolysis–Pinnick Tandem Transformation
Brian M. Cochran, Michael T. Corbett, Tiffany L. Correll, Yuan‐Qing Fang, Tawnya G. Flick, Siân C. Jones, Maria Victoria Silva Elipe, Austin G. Smith, John L. Tucker, Filisaty Vounatsos et al. · 2018 · The Journal of Organic Chemistry
Ubiquitin, SUMO, and Nedd8 as Therapeutic Targets in Cancer
Pierre Gâtel, Marc Piechaczyk, Guillaume Bossis · 2020 · Advances in experimental medicine and biology
Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2/MdmX Interaction
Ye Huang, Li Wang, Yuke Zhou, Jinping Bai, Ning Li, Zhengding Su, Xiyao Cheng · 2025 · Cells
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts
Huang, Licai, Wang, Jing, Fang, Bingliang, Meric-Bernstam, Funda, Roth, Jack A., Ha, Min Jin · 2022 · Scientific Reports
Mdm2 inhibitors as a platform for the design of P-glycoprotein inhibitors
Tatyana A. Grigoreva, Angelina A. Romanova, Aleksandra V. Sagaidak, Ворона Светлана Владимировна, Daria Novikova, Vyacheslav G. Tribulovich · 2020 · Bioorganic & Medicinal Chemistry Letters
p53 regulation by MDM2 contributes to self‐renewal and differentiation of basal stem cells in mouse and human airway epithelium
Sergio Garrido-Jiménez, Juan Francisco Barrera-López, Selene Díaz-Chamorro, Clara María Mateos-Quirós, Ignacio Rodriguez‐Blanco, Francisca Lourdes Márquez-Pérez, Maria Jesus Lorenzo, Francisco Centeno, Ángel Román, José María Carvajal-González · 2021 · The FASEB Journal
Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy
Abhilasha Sinha, Yong Zou, Ayushi S. Patel, Seungyeul Yoo, Feng Jiang, Takashi Sato, Ranran Kong, Hideo Watanabe, Jun Zhu, Pierre P. Massion et al. · 2022 · Cancers
Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy
Yanyu Jiang, Shuaishuai Ni, Biying Xiao, Lijun Jia · 2023 · Acta Pharmaceutica Sinica B
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations.
Xiaoshan Zhang, Ran Zhang, Huiqin Chen, Li Wang, Chenghui Ren, Apar Pataer, Shuhong Wu, Qing H. Meng, Min Jin Ha, Jeffrey S. Morris et al. · 2020 · PubMed Central
Structure and function of MDM2 and MDM4 in health and disease
Ivy Yiyi Zhu, Alec Lloyd, William R. Critchley, Queen Saikia, Dhananjay Jade, Aysha Divan, Elton Zeqiraj, Michael A. Harrison, Christopher John Brown, Sreenivasan Ponnambalam · 2025 · Biochemical Journal
Methods for the Discovery and Identification of Small Molecules Targeting Oxidative Stress-Related Protein–Protein Interactions: An Update
Xuexuan Wu, Qiuyue Zhang, Yuqi Guo, Hengheng Zhang, Xiaoke Guo, Qidong You, Lei Wang · 2022 · Antioxidants
Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
Qian Zhao, Shanshan Xiong, Can Chen, Hong-Ping Zhu, Xin Xie, Cheng Peng, Gu He, Bo Han · 2022 · Frontiers in Oncology
Synthesis and Biological Evaluation of Novel Dispiro-Indolinones with Anticancer Activity
Yan A. Ivanenkov, Maxim E. Kukushkin, Anastasia A. Beloglazkina, Radik R. Shafikov, Alexander A. Barashkin, Andrey A. Ayginin, Marina S. Serebryakova, Alexander G. Majouga, Dmitry Aleksandrovich Skvortsov, В. А. Тафеенко et al. · 2023 · Molecules
Targeting protein-protein interactions with low molecular weight and short peptide modulators: insights on disease pathways and starting points for drug discovery
Daniela Trisciuzzi, Bruno O. Villoutreix, Lydia Siragusa, Massimo Baroni, Gabriele Cruciani, Orazio Nicolotti · 2023 · Expert Opinion on Drug Discovery
Small-Molecule Inhibitors of Protein–Protein Interactions
Zhihong Liu, H. Chen, Eric A. Wold, Jia Zhou · 2016 · Elsevier eBooks
Small-molecule modulation of p53 protein-protein interactions
Ave Kuusk, Helen Boyd, Hongming Chen, Christian Ottmann · 2020 · Biological Chemistry
Query-guided protein–protein interaction inhibitor discovery
Sergio Celis, Fruzsina Hóbor, Thomas James, Gail J. Bartlett, Amaurys Ávila Ibarra, Deborah K. Shoemark, Zsófia Hegedüs, Kristina Hetherington, Derek N. Woolfson, Richard Barry Sessions et al. · 2021 · Chemical Science
Single-molecule analysis of interaction between p53TAD and MDM2 using aerolysin nanopores
Sohee Oh, Mi‐Kyung Lee, Seung‐Wook Chi · 2021 · Chemical Science
Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer
Ana Maria Montagut, Marc Armengol, Gema Gorjón-de-Pablo, Roger Estrada‐Tejedor, José Ignacio Borrell, Gaël Roué · 2022 · Seminars in Cell and Developmental Biology
Crystallographic mining of ASK1 regulators to unravel the intricate PPI interfaces for the discovery of small molecule
Ashish Kumar Agrahari, Madhu Dikshit, Shailendra Asthana · 2022 · Computational and Structural Biotechnology Journal
An update patent review of MDM2–p53 interaction inhibitors (2019–2023)
Aleksandra Twarda‐Clapa · 2024 · Expert Opinion on Therapeutic Patents
Harnessing p53 for targeted cancer therapy: new advances and future directions
Zdeněk Andrysík, Joaquin Maximiliano Espinosa · 2025 · Transcription
Optimization beyond AMG 232: Discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein–protein interaction
Yingcai Wang, Jiang Zhu, Jiwen Liu, Xiaoqi Chen, Jeff Mihalic, Jeffrey Deignan, Ming Yu, Daqing Sun, Frank Kayser, Lawrence R. McGee et al. · 2014 · Bioorganic & Medicinal Chemistry Letters
Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
Li Jun Ding, Zhiping Zhang, Chenhong Zhao, Lei Chen, Zhiqiang Chen, Jie Zhang, Yaxian Liu, Yesen Nie, Yanzhi He, Kai Liao et al. · 2021 · Journal of Experimental & Clinical Cancer Research
Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia
Angelo Aguilar, Jiuling Yang, Yangbing Li, Donna McEachern, Liyue Huang, Stevenchoukry Razzouk, Shaomeng Wang · 2024 · Journal of Medicinal Chemistry
p53–MDM2 and MDMX Antagonists
Constantinos G. Neochoritis, Natalia Estrada‐Ortiz, Kareem Khoury, Alexander S. S. Dömling · 2014 · Annual reports in medicinal chemistry
Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2–p53 interaction, in rats, dogs and monkeys:in vitro–in vivocorrelation
Qiuping Ye, Min Jiang, Wotang T. Huang, Yun Ling, Steven H. Olson, Daqing Sun, Guifen Xu, Xuelei Yan, Bradley K. Wong, Lixia Jin · 2015 · Xenobiotica
A Computational Investigation of Small-Molecule Engagement of Hot Spots at Protein–Protein Interaction Interfaces
David Daqiang Xu, Yubing Si, Samy O. Meroueh · 2017 · Journal of Chemical Information and Modeling
Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors
Jakub Stefaniak, Andrew M. Lewis, Daniel Conole, Sébastien R. G. Galan, Carole J. R. Bataille, Graham M. Wynne, Maria Paola Castaldi, Thomas Lundbäck, Angela J. Russell, K. Huber · 2018 · ACS Chemical Biology
A fluorinated indole‐based MDM 2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells
Łukasz Skalniak, Aleksandra Twarda‐Clapa, Constantinos G. Neochoritis, Ewa Surmiak, Monika Machula, Aneta Wiśniewska, Beata Łabuzek, Ameena Mohamed Ali, Sylwia Krzanik, Grzegorz Dubin et al. · 2019 · FEBS Journal
Faculty of Bioscience Engineering
Jonas Coussement · 2014
8-Triazolylpurines: Towards Fluorescent Inhibitors of the MDM2/p53 Interaction
Mariell Pettersson, David Bliman, Jimmy Jacobsson, Jesper R. Nilsson, Jaeki Min, Luigi I. Iconaru, Rodney Kiplin Guy, Richard W. Kriwacki, Joakim Andréasson, Morten Grøtli · 2015 · PLoS ONE
Design, Synthesis and Evaluation of 2,5-Diketopiperazines as Inhibitors of the MDM2-p53 Interaction
Mariell Pettersson, Maria Quant, Jaeki Min, Luigi I. Iconaru, Richard W. Kriwacki, Michael Brett Waddell, Rodney Kiplin Guy, Kristina Luthman, Morten Grøtli · 2015 · PLoS ONE
Rational Design, Synthesis, Separation, and Characterization of New Spiroxindoles Combined with Benzimidazole Scaffold as an MDM2 Inhibitor
Saeed Alshahrani, Abdullah Mohammed Al‐Majid, M. Ali, Abdullah Saleh Alamary, Marwa Muhammad Abu-Serie, Alexander S. S. Dömling, Muhammad Osama Shafiq, Zaheer Ul‐Haq, Assem Barakat · 2023 · Separations
The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Katrine Ingelshed, Diana Spiegelberg, Pavitra Kannan, Linnéa Påvénius, Jessica Hacheney, Long Jiang, Silke Eisinger, Danai Lianoudaki, Dilraj Lama, Francisca A. Castillo et al. · 2022 · Cancer Research Communications
Decoding the Role of MDM2 as a Potential Ubiquitin E3 Ligase and Identifying the Therapeutic Efficiency of Alkaloids against MDM2 in Combating Glioblastoma
Sudhanshu Sharma, Pravir Kumar · 2023 · ACS Omega
MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia
Ada Lerma Clavero, Paula Lafqvist Boqvist, Katrine Ingelshed, Cecilia Bosdotter, Saikiran K. Sedimbi, Long Jiang, Fredrik Wermeling, Bořivoj Vojtěšek, David Philip Lane, Pavitra Kannan · 2023 · Scientific Reports
The R882H substitution in the human de novo DNA methyltransferase DNMT3A disrupts allosteric regulation by the tumor supressor p53
Jonathan E. Sandoval, Norbert O. Reich · 2019 · Journal of Biological Chemistry
Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment
Xiuzhen Zhang, Tong Meng, Shuaishuai Cui, Ling Feng, Dongwu Liu, Qiuxiang Pang, Ping Wang · 2021 · Frontiers in Oncology
Phase 1 Concentration‐QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRT‐232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia
Taylor, Adekemi, Lee, Dana, Allard, Martine, Poland, Bill, Greg Slatter, J. · 2021 · Clinical Pharmacology in Drug Development
Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors
Dongjuan Si, Huijuan Luo, Xiaomeng Zhang, Kundi Yang, Hongmei Wen, Jian Li, Jian Li · 2021 · Bioorganic Chemistry
Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53
Douglas W. Brown, Perrin H. Beatty, John D. Lewis · 2022 · Cancers
ANXA1 promotes intrahepatic cholangiocarcinoma proliferation and growth by regulating glutamine metabolism through GOT1 stabilization
Yanyu Gong, Liwen Chen, Hao Wang, Dijie Zheng, Futang Li, Changhao Wu, Yongning Li, Yazhu Deng, Zhiwei He, Chao Yu · 2025 · Journal of Experimental & Clinical Cancer Research
Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
Vera V. Grinkevich, Aparna Vema, Karin Fawkner, Natalia Issaeva, Virginia Andreotti, Eleanor R. Dickinson, Elisabeth Hedström, Clemens Spinnler, Alberto Inga, Lars‐Gunnar Larsson et al. · 2022 · Frontiers in Molecular Biosciences
Virtual screening for inhibitors of the human TSLP:TSLPR interaction
Dries Van Rompaey, Kenneth Verstraete, Frank Peelman, Savvas N. Savvides, Koen Augustyns, Pieter Van der Veken, Hans L. De Winter · 2017 · Scientific Reports
Aqueous α‐Arylation of Mono‐ and Diarylethanone Enolates at Low Catalyst Loading
Iratxe Astarloa, Raúl SanMartı́n, María Teresa Herrero, Esther Domı́nguez · 2018 · Advanced Synthesis & Catalysis
Simultaneous Construction of Planar and Central Chiralities as Well as Unprecedented Axial Chirality on and around a Ferrocene Backbone
Hongjie Li, Peijing Jia, Naixin Qian, Shasha Li, Peng Jiao · 2019 · The Journal of Organic Chemistry
Perspectives on drug discovery strategies based on IDPs
Gustavo Fuertes, Laura Nevola, Santi Esteban-Martín · 2019 · Elsevier eBooks
Ligand-Based and Docking-Based Virtual Screening of MDM2 Inhibitors as Potent Anticancer Agents
Binghui Li, Junqi Ge, Ya-Li Wang, Lijun Wang, Qi Zhang, Cong Bian · 2021 · Computational and Mathematical Methods in Medicine
Regio- and Stereoselective Intermolecular 1,2-Difunctionalization of Terminal Alkynes: An Approach to Access ( Z )-β-Amidovinylsulfones
Rajesh Kumar, Deepak Bhadoria, Ruchir Kant, Atul Kumar · 2024 · The Journal of Organic Chemistry
Development of MDM2‐Targeting PROTAC for Advancing Bone Regeneration
Sol Jeong, Jae‐Kook Cha, Wasim Ahmed, Jaewan Kim, Minsup Kim, Kyung Tae Hong, Wonji Choi, Sunjoo Choi, Tae Hyeon Yoo, Hyun‐Ju An et al. · 2025 · Advanced Science
Epigenetic Alterations in Cancer: The Therapeutic Potential of Epigenetic Drugs in Cancer Therapy
Preeti Gupta · 2025 · Drugs and Drug Candidates
Targeting p53 activation: Recent therapeutic advances in cancer and diabetic macular edema
Zhiyi Wang, Shijie Zhang, Irakoze Loïca Mélita, Yujun Zhao · 2025 · European Journal of Medicinal Chemistry
Searching for novel MDM2/MDMX dual inhibitors through a drug repurposing approach
Keting Li, Wenshu Hu, Yingjie Wang, Wenxing Chen, Hongmei Wen, Jian Liu, Wěi Li, Bo Wang · 2023 · Journal of Enzyme Inhibition and Medicinal Chemistry
E3 Ubiquitin Ligases in Cancer and Their Pharmacological Targeting
Joseph Y. Ong, Jorge Z. Torres · 2019 · IntechOpen eBooks
Development of a Robust and Highly Selective Ru(II)-Catalyzed Dynamic Kinetic Resolution Used to Manufacture AMG 232
Austin G. Smith, Matthew M. Bio, John T. Colyer, Khalid Diker, Gilles Gorins, Siân C. Jones, Maria Victoria Silva Elipe, Jason S. Tedrow, Shawn D. Walker, Seb Caille · 2020 · Organic Process Research & Development
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
Seyed Saeed Pairawan, Argun Akçakanat, Scott Kopetz, Coya Tapia, Xiaofeng Zheng, Huiqin Chen, Min Jin Ha, Yasmeen Q. Rizvi, Vijaykumar R. Holla, Jing Wang et al. · 2022 · Scientific Reports
Synthesis and biological evaluation of dual MDM2/XIAP inhibitors based on the tetrahydroquinoline scaffold
Najah G. Albadari, Yang Xie, Tao Liu, Rui Wang, Lubing Gu, Muxiang Zhou, Zhongzhi Wu, Wěi Li · 2023 · European Journal of Medicinal Chemistry
Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma
Dena Panovska, Pouya Nazari, Basiel Cole, Pieter-Jan Creemers, Marleen Derweduwe, Lien Solie, Sofie Van Gassen, Annelies Claeys, Tatjana Verbeke, Elizabeth F. Cohen et al. · 2023 · Cellular and Molecular Life Sciences
SNPs Give LACTB Oncogene‐Like Functions and Prompt Tumor Progression via Dual‐Regulating p53
Guanyu Huang, Jiajun Zhang, Yu Xu, Fei Ling Wu, Yiwei Fu, Xuelin Zhang, Hanxiao Yin, Yuanyuan You, Peng Zhao, Weihai Liu et al. · 2024 · Advanced Science
A structure-based virtual screening identifies a novel MDM2 antagonist in the activation of the p53 signaling and inhibition of tumor growth
Qing-yong Hu, Lei Li, Yu-huang Li, Haibo Zhang, Tao Deng, Yang Liu, Feng-tian Li, Zhi‐Xiong Jim Xiao, Yang Cao · 2024 · Acta Pharmacologica Sinica
Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci
Yuri Frosi, Ken‐ichi Inoue, Siti Radhiah Ramlan, David Philip Lane, Taku Watanabe, Christopher John Brown · 2019 · Scientific Reports
Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX
Yali Wang, Bo Ji, Zhongshui Cheng, Lianghui Zhang, Yingying Cheng, Yingying Li, Jin Tao Ren, Wenbo Liu, Yuanyuan Ma · 2022 · Molecules
Molecular investigation of the dual inhibition mechanism for targeted P53 regulator MDM2/MDMX inhibitors
Xiaoyu Zhao, Danyang Xiong, Song Luo, Lili Duan · 2022 · Physical Chemistry Chemical Physics
Probing Protein Surfaces: QSAR Analysis with Helix Mimetics
Valeria Azzarito, Philip R. Rowell, Anna Barnard, Thomas A. Edwards, Andrew Macdonald, Stuart L. Warriner, Andrew John Wilson · 2015 · ChemBioChem
The Development of New Spirooxindoles Targeting the p53–MDM2 Protein-Protein Interactions for Cancer Therapy
Bin Yu, Hong‐Min Liu · 2018 · Springer eBooks
MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Yan Yu Zhu, Herui Wang, Asha Thuraisamy · 2019 · Elsevier eBooks
Development and structural characterization of an engineered multi-copper oxidase reporter of protein–protein interactions
Barindra Sana, Sharon Min Qi Chee, Jantana Wongsantichon, Sarada S. Raghavan, Robert Charles Robinson, Farid John Ghadessy · 2019 · Journal of Biological Chemistry
A concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT
Atchimnaidu Siriki, Graham Ragland, Janardhan Vasireddy, Satish K. Chitneni · 2025 · Bioorganic & Medicinal Chemistry Letters
Targeting MDM2 for the development of a new cancer therapy: progress and challenges
Angelo Aguilar, Junius Eugene Thomas, Shaomeng Wang · 2023 · Medicinal Chemistry Research
Affinity-based protein profiling of MDM2 inhibitor Navtemadlin
Amrita Date, Archie Wall, Peiyu Zhang, Jack W. Houghton, Jianan Lu, Adam Thomas, Tristan Kovačič, Andrew John Wilson, Edward W. Tate, Anna Barnard · 2025 · Chemical Science